Cross-protective immunity to Leishmania amazonensis is mediated by CD4+ and CD8+ epitopes of Leishmania donovani nucleoside hydrolase terminal domains

Frontiers in Immunology

Volumn 5, Issue MAY, 2014, Pages

  Nico, Dirlei ^a   Gomes, Daniele Crespo ^a   Alves Silva, Marcus Vinícius ^a   Freitas, Elisangela Oliveira ^a   Morrot, Alexandre ^a   Bahia, Diana ^b,c   Palatnik, Marcos ^a   Rodrigues, Mauricio M ^b   Palatnik de Sousa, Clarisa B ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Cross protection; Cutaneous leishmaniasis; Diffuse cutaneous leishmaniasis; Nucleoside hydrolases; Prophylaxis; Recombinant vaccines; Visceral leishmaniasis

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M; INTERLEUKIN 10; NUCLEOSIDASE; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOOT PAD; HAMSTER; IMMUNE RESPONSE; IMMUNIZATION; LEISHMANIA DONOVANI; LEISHMANIASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE LOAD; PROTEIN EXPRESSION; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY;

EID: 84905438836     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00189     Document Type: Article

References (47)

1. Kedzierski L. Leishmaniasis vaccine: where are we today? J Glob Infect Dis (2010) 2(2):177-85. doi: 10.4103/0974-777X.62881
2. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One (2012) 7(5):e35671. doi:10.1371/journal.pone.0035671
3. Kedzierski L, Zhu Y, Handman E. Leishmania vaccines: progress and problems. Parasitology (2006) 133(Suppl S):87-112. doi:10.1017/S0031182006001831
4. Lainson R, Shaw JJ. Evolution, classification and geographic distribution. 1st ed. In: Peters W, Killick Kendrick R, editors. The Leishmaniases in Biology and Medicine. Biology and Epidemiology. (Vol. 2), London, UK: Academic Press (1987). p. 1-120.
5. Rougeron V, Bañuls AL, Carme B, Simon S, Couppié P, Nacher M, et al. Reproductive strategies and population structure in Leishmania: substantial amount of sex in Leishmania Viannia guyanensis. Mol Ecol (2011) 20(15):3116-27. doi:10.1111/j.1365-294X.2011.05162.x
6. Dye C. The logic of visceral leishmaniasis control. Am J Trop Med Hyg (1996) 55(2):125-30.
7. Palatnik-de-Sousa CB. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine (2008) 26(14):1709-24. doi:10.1016/j.vaccine.2008.01.023
8. Duthie MS, Raman VS, Piazza FM, Reed SG. The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine (2012) 30(2):134-41. doi:10.1016/j.vaccine.2011.11.005
9. Antunes CM, Mayrink W, Magalhaes PA, Costa CA, Melo MN, Dias M, et al. Controlled field trials of a vaccine against new world cutaneous leishmaniasis. Int J Epidemiol (1986) 15(4):572-80. doi:10.1093/ije/15.4.572
10. Vélez ID, Gilchrist K, Arbelaez MP, Rojas CA, Puerta JA, Antunes CM, et al. Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. Trans R Soc Trop Med Hyg (2005) 99(8):593-8. doi:10.1016/j.trstmh.2005.04.002
11. Gradoni L, Foglia Manzillo V, Pagano A, Piantedosi D, De Luna R, Gramiccia M, et al. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine (2005) 23(45):5245-51. doi:10.1016/j.vaccine.2005.07.001
12. Trigo J, Abbehusen M, Netto EM, Nakatani M, Pedral-Sampaio G, de Jesus RS, et al. Treatment of canine visceral leishmaniasis by the vaccine Leish-111f + MPL-SE. Vaccine (2010) 28(19):3333-40. doi:10.1016/j.vaccine.2010.02.089
13. da Silva VO, Borja-Cabrera GP, Correia Pontes NN, de Souza EP, Luz KG, Palatnik M, et al. A phase III trial of Efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine (2000) 19(9-10):1082-92.
14. Borja-Cabrera GP, Santos FN, Bauer FS, Parra LE, Menz I, Morgado AA, et al. Immunogenicity assay of the Leishmune® vaccine against canine visceral leishmaniasis in Brazil. Vaccine (2008) 26(39):4991-7. doi:10.1016/j.vaccine.2008.07.029
15. Palatnik-de-Sousa CB, Barbosa AF, Oliveira SM, Nico D, Bernardo RR, Santos WR, et al. The FML-vaccine against canine visceral leishmaniasis: from the second generation to the synthetic vaccine. Expert Rev Vaccines (2008) 7(6):833-51. doi:10.1586/14760584.7.6.833
16. Saraiva EM, de Figueiredo Barbosa A, Sanots FN, Borja-Cabrera GP, Nico D, Souza LP, et al. The FML-vaccine (Leishmune®) against canine visceral leishmaniasis: a transmission blocking vaccine. Vaccine (2006) 24(13):2423-31. doi:10.1016/j.vaccine.2005.11.061
17. Palatnik-de-Sousa CB, Silva-Antunes I, Morgado Ade A, Menz I, Palatnik M, Lavor C. Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune® in Brazilian endemic areas. Vaccine (2009) 27(27):3505-12. doi:10.1016/j.vaccine.2009.03.045
18. Palatnik-de-Sousa CB, Gomes EM, de Souza EP, dos Santos WR, de Macedo SR, de Medeiros LV, et al. The FML (fucose mannose ligand) of Leishmania donovani. A new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar. Rev Soc Bras Med Trop (1996) 29(2):153-63. doi:10.1590/S0037-86821996000200008
19. Palatnik-de-Sousa CB, Dutra HS, Borojevic R. Leishmania donovani surface glycoproteins GP36, is the major immunogen component of the fucose mannose ligand (FML). Acta Trop (1993) 53(1):59-72. doi:10.1016/0001-706X(93)90006-W
20. Iovane E, Giabbai B, Muzzolini L, Matafora V, Fornili A, Minici C, et al. Structural basis for substrate specificity in group I nucleoside hydrolases. Biochemistry (2008) 47(15):4418-26. doi:10.1021/bi702448s
21. Versées W, Goeminne A, Berg M, Vandemeulebroucke A, Haemers A, Augustyn K, et al. Crystal structures of T. vivax nucleoside hydrolase in complex with new potent and specific inhibitors. Biochim Biophys Acta (2009) 1794(6):953-60. doi:10.1016/j.bbapap.2009.02.011
22. Santana DM, Borja-Cabrera GP, Paraguai de Souza E, Sturm NR, Palatnik-de-Sousa CB, Campbell DA. Nucleoside hydrolase from Leishmania (L.) donovani is an antigen diagnostic for visceral leishmaniasis. Mol Biochem Parasitol (2002) 120(2):315-9. doi:10.1016/S0166-6851(02)00010-5
23. Mauricio IL, Yeo M, Baghaei M, Doto D, Pratlong F, Zemanova E, et al. Towards multilocus sequence typing of the Leishmania donovani complex: resolving genotypes and haplotypes for five polymorphic metabolic enzymes (ASAT, GPI, NH1, NH2, PGD). Int J Parasitol (2006) 36(7):757-69. doi:10.1016/j.ijpara.2006.03.006
24. Lukes J, Mauricio IL, Schönian G, Dujardin JC, Soteriadou K, Dedet JP, et al. Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc Nat Acad Sci U S A (2007) 104(22):9375-80. doi:10.1073/pnas.0703678104
25. Shi W, Schramm VL, Almo SC. Nucleoside hydrolase from Leishmania major. Cloning, expression, catalytic properties, transition state inhibitors, and the 2.5-å crystal structure. J Biol Chem (1999) 274(30):21114-20. doi:10.1074/jbc.274.30.21114
26. Blast-Basic Local Alignment Search Tool. National Institute of Heath (NIH) (2014). Available from: http://blast.ncbi.nlm.nih.gov/Blast.cgi
27. Paraguai de Souza E, Bernardo RR, Palatnik M, Palatnik-de-Sousa CB. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine (2001) 19(23-24):3104-15. doi:10.1016/S0264-410X(01)00031-7
28. Al-Wabel MA, Tonui WK, Cui L, Martin SK, Titus RG. Protection of susceptible BALB/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania. Am J Trop Med Hyg (2007) 77(6):1060-5.
29. Aguilar-Be I, Zardo RS, Paraguai de Souza E, Borja-Cabrera GP, Rosado-Vallado M, Mut-Martin M, et al. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun (2005) 73(2):812-9. doi:10.1128/IAI.73.2.812-819.2005
30. Chalé-Balboa WG, Mut-Martin M, Ramirez-Sierra MJ, Garcia-Miss MR, Dumonteil E. A combination DNA vaccine encoding nucleoside hydrolase 36 and glycoprotein 63 protects female but not male hamsters against Leishmania mexicana. Parasite (2009) 16(3):227-30. doi:10.1051/parasite/2009163227
31. Souza LOP, Palatnik-de-Sousa CB. The nucleoside hydrolase DNA vaccine VR1012NH36 in prophylactic vaccination against mice tegumentar leishmaniasis. Procedia Vaccinol (2009) 1(1):120-3. doi:10.1016/j.provac.2009.07.022
32. Gamboa-León R, Paraguai de Souza E, Borja-Cabrera GP, Santos FN, Miyashiro LM, Pinheiro RO, et al. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of L. donovani. Vaccine (2007) 24(22):4863-73. doi:10.1016/j.vaccine.2006.03.005
33. Borja-Cabrera GP, Santos FB, Nico D, Gravino AE, Manna L, Palatnik M, et al. The Leishmuneots nucleoside hydrolase DNA vaccine as an aid in immunotherapy of canine visceral leishmaniasis. Procedia Vaccinol (2012) 6:64-73. doi:10.1016/j.provac.2012.04.009
34. Nico D, Claser C, Travassos LR, Palatnik M, Soares IS, Rodrigues MM, et al. Adaptive immunity against Leishmania nucleoside hydrolase maps its C-terminal domain as the target of the CD4+ T cell-driven protective response. Plos Negl Trop Dis (2010) 4(11):e866. doi:10.1371/journal.pntd.0000866
35. Real F, Vidal RO, Carazzolle MF, Mondego JM, Costa GG, Herai RH, et al. The genome sequence of Leishmania (Leishmania) amazonensis: functional annotation and extended analysis of gene models. DNA Res (2013) 20(6):567-81. doi:10.1093/dnares/dst031
36. de Oliveira Cardoso FO, Souza CSF, Mendes VG, Abreu-Silva AL, Costa SCG, Calabrese KS, et al. Immunopathological studies of Leishmania amazonensis infection in resistant and in susceptible mice. J Infect Dis (2010) 201(12):1933-40. doi:10.1086/652870
37. Costa MM, Penido M, dos Santos MS, Doro D, de Freitas E, Michalik MS, et al. Improved canine and human visceral leishmaniasis immunodiagnosis using combinations of synthetic peptides in enzyme-linked immunosorbent assay. PLoS Negl Trop Dis (2012) 6(5):e1622. doi:10.1371/journal.pntd.0001622
38. Parra-López C, Calvo-Calle M, Cameron TO, Vargas LE, Salazar LM, Patarroyo ME, et al. Major histocompatibility complex and T cell interactions of a universal T-cell epitope from Plasmodium falciparum circumsporozoite protein. J Biol Chem (2006) 281(21):14907-17. doi:10.1074/jbc.M511571200
39. Hernández-Ruiz J, Salaiza-Suazo N, Carrada G, Escoto S, Ruiz-Remigio A, Rosenstein Y, et al. CD8 cells of patients with diffuse cutaneous leishmaniasis display functional exhaustion: the latter is reversed, in vitro, by TLR2 agonists. PLoS Negl Trop Dis (2010) 4(11):e871. doi:10.1371/journal.pntd.0000871
40. Basu R, Roy S, Walden P. HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages. J Infect Dis (2007) 195(9):1373-80. doi:10.1086/513439
41. Bertholet S, Goto Y, Carter L, Bhatia A, Howard RF, Carter D, et al. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine (2009) 27(50):7036-45. doi:10.1016/j.vaccine.2009.09.066
42. Kedzierska K, Curtis JM, Valkenburg SA, Hatton LA, Kiu H, Doherty PC, et al. Induction of protective CD4+ T cell-mediated immunity by a Leishmania peptide delivered in recombinant influenza viruses. PLoS One (2012) 7(3):e33161. doi:10.1371/journal.pone.0033161
43. Fernandes AP, Coelho EA, Machado-Coelho GL, Grimaldi G Jr, Gazzinelli RT. Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives. Curr Opin Microbiol (2012) 15(4):476-85. doi:10.1016/j.mib.2012.05.002
44. Darrah PA, Patel DT, De Luca PM, Lindsay RWB, Davey DF, Flynn BG, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med (2007) 13(7):843-50. doi:10.1038/nm1592
45. Todd SJ, Moir AJ, Johnson MJ, Moir A. Genes of Bacillus cereus and Bacillus anthracis encoding proteins of the exosporium. J Bacteriol (2003) 185(11):3373-8. doi:10.1128/JB.185.11.3373-3378.2003
46. Mitterbauer R, Karl T, Adam G. Saccharomyces cerevisiae URH1 (encoding uridine-cytidine N-ribohydrolase): functional complementation by a nucleoside hydrolase from a protozoan parasite and by a mammalian uridine phosphorylase. Appl Environ Microbiol (2002) 68(3):1336-43. doi:10.1128/AEM.68.3.1336-1343.2002
47. Ribeiro JM, Valenzuela JG. The salivary purine nucleosidase of the mosquito, Aedes aegypti. Insect Biochem (2003) 33(1):13-22. doi:10.1016/S0965-1748(02)00078-4